Refining selection criteria to further increase survival benefit in liver transplantation for unresectable colorectal liver metastases

Matteo Serenari, Matteo Ravaioli


Liver transplantation (LT) for hepatocellular carcinoma (HCC) was characterized in its early experience by high recurrence rates due to extensive tumor burden (1). Only after the adoption of Milan criteria (2), LT was recognized as a standard treatment for HCC (3). Besides HCC, other hepatic malignancies were proposed to be treated in the past with LT but due to the poor results observed (4), these indications were abandoned. Among them, colorectal liver metastases (CRLM) were considered an absolute contraindication until recently.